A critical Sample Size Reestimation (SSRE) for the RCC Phase IIb trial is expected in the fourth quarter of 2026 to confirm powering assumptions at the 50% enrollment mark. Management intends to ...

ProT-096 designed to address critical gaps in immune recovery for patients with refractory hematologic malignancies through a ...

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- ...

Issued on behalf of Rua Gold Inc.After-tax NPV5% of US$42M at base case and US$113M at spot gold, 95% gold and 85% antimony recovery, no-cyanide ...

Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) ...

Researchers identify early brain connectivity signals that may help predict treatment response after minimally invasive ...

Fast Track status aims to accelerate development of an autologous dendritic cell immunotherapy for advanced cutaneous ...

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or th ...

A randomized trial published in the American Journal of Psychiatry has found that magnetic seizure therapy (MST) achieved ...

Scar-driven changes in joint tissue may underlie treatment resistance in rheumatoid arthritis, opening the door to new targeted therapies.

BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, today announced the signing of a binding Heads of Terms agreement with Wellington Zhaotai ...

Drug-resistant epilepsy affects millions of people worldwide and remains one of the most difficult neurological disorders to treat. For patients whose seizures continue despite medication, surgical ...